Brain Health: CTAD 2026 – Five-Year Results for the Alzheimer's Drug Lecanemab
Send us Fan Mail Conference news from CTAD 2026 (Clinical Trials on Alzheimer's Disease, Boston). Eisai and Biogen presented five-year data for lecanemab (Leqembi) from the Clarity AD study and its open-label extension, in which 351 people received continuous treatment for five years. Compared with outside natural-history data from ADNI, the treated group showed 2.05 points less worsening on CDR-SB at five years, and in a low-tau subgroup 62% had improved CDR-SB scores from baseline. We walk through the numbers, the ARIA safety data by year, and the caveats: after 18 months there was no placebo group, the comparisons use external cohorts, and the results have not yet been peer reviewed. Sources: Eisai and Biogen announcement: https://www.globenewswire.com/news-release/2026/11/16/3404222/0/en/new-five-year-lecanemab-data-from-clarity-ad-study-long-term-extension-presented-at-ctad-2026.html BioArctic announcement: https://news.cision.com/bioarctic/r/five-year-data-of-continuous-leqembi--treatment-show-increasing-benefit-over-time,c4425299 ClinicalTrials.gov NCT03887455: https://clinicaltrials.gov/study/NCT03887455 CTAD 2026: https://www.ctad-alzheimer.com/ This episode was generated with AI from a written summary of public reports. It is an educational news discussion and is not medical advice. Talk with your own doctor about any treatment decisions. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters